AstraZeneca & Daiichi Breakthrough Trial: New Breast Cancer Therapy Tested
Daiichi Sankyo and AstraZeneca have begun dosing the first patient in two global, randomized Phase 3 trials of their...
Jon Napitupulu
Gilead’s $848M Bet on Compugen’s Revolutionary Therapy
Gilead Sciences, Inc. has entered into an agreement with Israeli company Compugen Ltd., a clinical-stage cancer immunotherapy firm, to...
Zurzuvae: New Hope Pill for Moms with Post-Partum Depression
Sage Therapeutics, Inc. and Biogen Inc. have announced the availability of ZURZUVAE™ (zuranolone) by prescription in the United States...
FDA Nods to Padcev-Keytruda for Bladder Cancer
Pfizer Inc. and Astellas Pharma Inc. have announced the FDA’s approval of PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC])...
BMS’s RELATIVITY-123 Trial Fail: A Devastating End
Bristol Myers Squibb announced the discontinuation of the Phase 3 RELATIVITY-123 trial, which was evaluating the fixed-dose combination of...
Pfizer Seals Deal: Seagen Now Acquired for $229/Share
Pfizer Inc. has announced the completion of its acquisition of Seagen Inc., marking a significant expansion in its commitment...
Pfizer Bold 2024 Forecast: A New Era Dawns
Pfizer Inc. has provided its financial forecast guidance for the full year of 2024, accounting for the anticipated impact...
ACRO Unveils Power Squad for 2024: Meet the New Faces
The Association of Clinical Research Organizations (ACRO) announced the election of Peyton Howell, Chief Operating & Growth Officer at...
Miracle CAR T-Cell Hope from Gilead for Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), has presented encouraging data from various studies on the CAR T-cell therapies Tecartus®...
Mooresville Locals Breathe Easy with Sanofi COPD Study
A new clinical trial, known as the AERIFY-2 study, is underway in Mooresville, N.C., focusing on chronic obstructive pulmonary...